Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 19.3 %

Akari Therapeutics stock opened at $1.09 on Wednesday. The stock has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $2.40. Akari Therapeutics has a 52-week low of $0.90 and a 52-week high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.